CV risk in patients with type 2 diabetes and CVD
Join our expert panel as they discuss the latest evidence and guideline recommendations for reducing CV risk for patients with both type 2 diabetes and CVD.
About the webinar
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for people with diabetes and the largest contributor to the direct and indirect costs of diabetes. Approximately 65% of all CVD deaths in Australia occur in people with diabetes or prediabetes.
Over the last few years, the management of type 2 diabetes has rapidly grown more complex. Recent developments include new medicines, emerging clinical trial results that provide cardiovascular (CV) outcome data related to blood glucose-lowering medicines, and an update to clinical guidelines. Now, more than ever, a clear, stepped approach is necessary to navigate the plethora of options available and reduce risk of microvascular and macrovascular complications.
Join our multidisciplinary panel of experts for a webinar discussion on the prevention of CV events in patients with both type 2 diabetes and CVD. Discussion will cover:
- Evidence-based strategies to reduce CV risk for patients with diabetes and CVD
- Advice on how to individualise choice of blood glucose-lowering agents
- The latest Australian blood glucose treatment algorithm for type 2 diabetes
- An update on the latest CV outcome trial data and how this impacts your practice
Meet the panel
The management of type 2 diabetes in patients who have CVD calls for a holistic and multidisciplinary approach. For this webinar we have selected a panel that brings together expertise from general practice, endocrinology, nursing and diabetes education.